Będkowska Grażyna Ewa, Gacuta Ewa, Zajkowska Monika, Głażewska Edyta Katarzyna, Osada Joanna, Szmitkowski Maciej, Chrostek Lech, Dąbrowska Milena, Ławicki Sławomir
Department of Haematological Diagnostics, Medical University Bialystok, Waszyngtona 15A, 15-269, Bialystok, Poland.
Department of Perinatology, Medical University Bialystok, Bialystok, Poland.
J Ovarian Res. 2017 Jun 29;10(1):39. doi: 10.1186/s13048-017-0338-z.
MMP-7 and TIMP-1 may play a role in the pathogenesis of cancer disease. In this study we investigated plasma levels of selected metalloproteinase and its tissue inhibitor in comparison to plasma levels of the commonly accepted tumor markers (CA 125 and HE4) in selected histological types of epithelial ovarian cancer patients as compared to control groups: patients with a benign ovarian tumor and healthy subjects. Plasma levels of MMP-7 and TIMP-1 were determined using ELISA, CA 125 and HE4 - by CMIA methods.
Plasma levels of all biomarkers studied were significantly higher in ovarian cancer patients as compared to both control groups. MMP-7 demonstrated comparable to HE4 or CA125 values of diagnostic sensitivity (SE: 61%; 68%; 58%, respectively), specificity (SP: 95%; 95%; 98%, respectively), positive (PPV: 93%; 96%; 98%, respectively) and negative predictive values (NPV: 61%; 66%; 60%, respectively) in the groups tested. The combined use of the aforementioned biomarkers resulted in a further increase in diagnostic criteria and AUC, especially in the early stages of the disease.
These findings suggest the usefulness of combining MMP-7 with CA 125 and HE4 in the diagnosis of epithelial ovarian cancer as a new tumor marker panel.
基质金属蛋白酶-7（MMP-7）和金属蛋白酶组织抑制因子-1（TIMP-1）可能在癌症发病机制中发挥作用。在本研究中，我们调查了特定组织学类型的上皮性卵巢癌患者血浆中选定的金属蛋白酶及其组织抑制剂的水平，并与对照组（良性卵巢肿瘤患者和健康受试者）血浆中公认的肿瘤标志物（CA 125和人附睾蛋白4（HE4））水平进行比较。采用酶联免疫吸附测定法（ELISA）测定MMP-7和TIMP-1的血浆水平，采用化学发光微粒子免疫分析（CMIA）方法测定CA 125和HE4。
与两个对照组相比，卵巢癌患者所有研究生物标志物的血浆水平均显著更高。在测试组中，MMP-7的诊断敏感性（SE分别为61%、68%、58%）、特异性（SP分别为95%、95%、98%）、阳性预测值（PPV分别为93%、96%、98%）和阴性预测值（NPV分别为61%、66%、60%）与HE4或CA125相当。联合使用上述生物标志物可进一步提高诊断标准和曲线下面积（AUC），尤其是在疾病早期。
这些发现表明，将MMP-7与CA 125和HE4联合用于上皮性卵巢癌诊断作为一种新的肿瘤标志物组合具有实用性。
